Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Sold by Maven Securities LTD

Maven Securities LTD reduced its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 80.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 170,000 shares of the company's stock after selling 680,000 shares during the period. Maven Securities LTD owned about 0.11% of Wave Life Sciences worth $2,103,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Millennium Management LLC grew its holdings in Wave Life Sciences by 38.7% during the fourth quarter. Millennium Management LLC now owns 1,180,838 shares of the company's stock worth $14,607,000 after acquiring an additional 329,173 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Wave Life Sciences by 23.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 52,392 shares of the company's stock worth $648,000 after purchasing an additional 9,907 shares during the period. Deutsche Bank AG grew its stake in shares of Wave Life Sciences by 57.6% during the 4th quarter. Deutsche Bank AG now owns 70,466 shares of the company's stock worth $872,000 after purchasing an additional 25,756 shares during the period. D. E. Shaw & Co. Inc. increased its holdings in shares of Wave Life Sciences by 71.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 716,253 shares of the company's stock valued at $8,860,000 after purchasing an additional 297,792 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in shares of Wave Life Sciences by 14.6% in the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock valued at $83,033,000 after purchasing an additional 853,589 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.

Wave Life Sciences Stock Performance

Wave Life Sciences stock traded up $0.03 during trading on Friday, reaching $6.33. The company had a trading volume of 1,306,010 shares, compared to its average volume of 1,285,047. The firm's 50-day simple moving average is $7.42 and its 200 day simple moving average is $10.87. Wave Life Sciences Ltd. has a 1-year low of $4.25 and a 1-year high of $16.74. The firm has a market capitalization of $975.67 million, a PE ratio of -5.70 and a beta of -0.92.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of $9.18 million during the quarter, compared to analyst estimates of $11.65 million. During the same period in the prior year, the business posted ($0.24) EPS. Analysts anticipate that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on WVE shares. Wedbush assumed coverage on shares of Wave Life Sciences in a research report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 price target on the stock. Cantor Fitzgerald started coverage on Wave Life Sciences in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 target price on the stock. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Finally, StockNews.com cut Wave Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $21.17.

Insiders Place Their Bets

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the sale, the director now owns 16,115 shares of the company's stock, valued at $157,443.55. The trade was a 39.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This trade represents a 33.31% decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.